No Data
No Data
Nurix Therapeutics Says Patients Respond Well to Potential Non-Hodgkin Lymphoma Treatment in Phase 1 Trial
Nurix Therapeutics (NRIX) said Sunday an ongoing phase 1a/b clinical trial of its drug NX-5948 is yielding what one of its researchers called "impressive" results for the treatment of adult patients w
Express News | Reported Sunday, Nurix Therapeutics Confirms Efficacy Of NX-5948 In Relapsed CLL With 69.2% Objective Response, Presented At EHA2024
Express News | Nurix Therapeutics Inc : JP Morgan Raises Target Price to $31 From $30
Express News | Nurix Therapeutics-Response Rate of 69.2% Observed in Heavily Pretreated Patient Population Including Patients With Btk Inhibitor Resistance Mutations
Express News | Nurix Therapeutics Inc - Clinical Responses in Cll Patients Were Rapid and Deepening With Longer Time on Treatment
Express News | Nurix Therapeutics Inc - Nurix Intends to Advance Nx-5948 Into Pivotal Trial(S) in 2025
No Data